NO20054120D0 - Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav - Google Patents

Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav

Info

Publication number
NO20054120D0
NO20054120D0 NO20054120A NO20054120A NO20054120D0 NO 20054120 D0 NO20054120 D0 NO 20054120D0 NO 20054120 A NO20054120 A NO 20054120A NO 20054120 A NO20054120 A NO 20054120A NO 20054120 D0 NO20054120 D0 NO 20054120D0
Authority
NO
Norway
Prior art keywords
azacycloalkane
arylvinyl
compounds
processes
preparation
Prior art date
Application number
NO20054120A
Other languages
English (en)
Other versions
NO331920B1 (no
NO20054120L (no
Inventor
Michel Cheve
Arielle Genevois-Borella
Gary Maurice Dull
Jeffrey Daniel Schmitt
Marc Capet
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of NO20054120D0 publication Critical patent/NO20054120D0/no
Publication of NO20054120L publication Critical patent/NO20054120L/no
Publication of NO331920B1 publication Critical patent/NO331920B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
NO20054120A 2003-03-05 2005-09-05 Arylvinylazacykloalkan-forbindelser, slike forbindelser for behandling av sykdom samt fremgangsmater for deres fremstilling NO331920B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/379,868 US7098331B2 (en) 2003-03-05 2003-03-05 Arylvinylazacycloalkane compounds and methods of preparation and use thereof
PCT/US2004/006530 WO2004078752A1 (en) 2003-03-05 2004-03-04 Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Publications (3)

Publication Number Publication Date
NO20054120D0 true NO20054120D0 (no) 2005-09-05
NO20054120L NO20054120L (no) 2005-10-03
NO331920B1 NO331920B1 (no) 2012-04-30

Family

ID=32926772

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20054120A NO331920B1 (no) 2003-03-05 2005-09-05 Arylvinylazacykloalkan-forbindelser, slike forbindelser for behandling av sykdom samt fremgangsmater for deres fremstilling
NO20091888A NO332293B1 (no) 2003-03-05 2009-05-14 Arylvinylazacykloalkan-forbindelser, fremgangsmater for deres fremstilling, farmasoytisk preparat omfattende slike samt anvendelse derav for behandling av sykdom
NO20092231A NO20092231L (no) 2003-03-05 2009-06-09 Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20091888A NO332293B1 (no) 2003-03-05 2009-05-14 Arylvinylazacykloalkan-forbindelser, fremgangsmater for deres fremstilling, farmasoytisk preparat omfattende slike samt anvendelse derav for behandling av sykdom
NO20092231A NO20092231L (no) 2003-03-05 2009-06-09 Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav

Country Status (32)

Country Link
US (8) US7098331B2 (no)
EP (3) EP2085395B1 (no)
JP (3) JP4663627B2 (no)
KR (4) KR101185541B1 (no)
CN (3) CN101255155A (no)
AR (3) AR043469A1 (no)
AT (3) ATE496046T1 (no)
AU (3) AU2004217903B2 (no)
BR (1) BRPI0409576A (no)
CA (1) CA2516514C (no)
CL (1) CL2004000452A1 (no)
CY (2) CY1110391T1 (no)
DE (2) DE602004013553D1 (no)
DK (2) DK1601670T3 (no)
EA (3) EA019240B1 (no)
ES (3) ES2309507T3 (no)
GT (1) GT200400033A (no)
HK (3) HK1084949A1 (no)
IL (3) IL170155A (no)
JO (1) JO2488B1 (no)
MX (1) MXPA05009386A (no)
NO (3) NO331920B1 (no)
NZ (1) NZ541795A (no)
PA (1) PA8597201A1 (no)
PE (1) PE20040930A1 (no)
PL (5) PL1601670T3 (no)
PT (2) PT2085395E (no)
SI (2) SI2085395T1 (no)
TW (3) TW200927746A (no)
UY (1) UY28218A1 (no)
WO (1) WO2004078752A1 (no)
ZA (1) ZA200506790B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
FR2896800B1 (fr) 2006-01-30 2008-04-11 Servier Lab Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
EP2647373A1 (en) * 2008-05-12 2013-10-09 Targacept, Inc. Methods for preventing the development of retinopathy by the oral administration of exo-S-mecamylamine.
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
ES2820857T3 (es) * 2008-12-01 2021-04-22 Oyster Point Pharma Inc Síntesis y formas de sal novedosas de (R)-5-((E)-2-pirrolidin-3-ilvinil)pirimidina
TW201024283A (en) * 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
CA2763551A1 (en) * 2009-06-17 2010-12-23 Targacept, Inc. Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands
EP2509982A1 (en) 2009-12-07 2012-10-17 Targacept, Inc. 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands
MX2012010491A (es) * 2010-03-11 2013-01-25 Targacept Inc Compuestos arilvinilazacicloalcano para la constipacion.
US20110274628A1 (en) * 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US20140081714A1 (en) * 2012-09-19 2014-03-20 Salesforce.Com, Inc. Systems and methods of rewarding users in an on-demand system
US20140278929A1 (en) * 2013-03-15 2014-09-18 Yahoo! Inc. System and method identifying opportunities for advertising entities based on user goal achievement
EP3970724A1 (en) 2016-04-07 2022-03-23 Oyster Point Pharma, Inc. Methods of treating ocular conditions
KR101848601B1 (ko) * 2016-07-27 2018-04-12 송기봉 일회용 위생 티슈
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
CN112638364A (zh) 2018-07-10 2021-04-09 奥伊斯特普安生物制药公司 用于治疗眼部病症的正向别构调节剂和烟碱型乙酰胆碱受体激动剂的组合
EP4142734A1 (en) 2020-04-28 2023-03-08 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5187166A (en) 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
IT1274018B (it) 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6437138B1 (en) 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
HU226859B1 (en) 1997-10-27 2009-12-28 Neurosearch As Phenyl- or heteroaryl-homopiperazines, their use and medicaments containing them
WO2000075110A1 (en) 1999-06-07 2000-12-14 Targacept, Inc. Pharmaceutical compositions and methods for use
EP1212319A2 (en) 1999-09-14 2002-06-12 Abbott Laboratories 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
JP2003513054A (ja) 1999-11-01 2003-04-08 ターガセプト，インコーポレイテッド アリールオレフィンアザ環式化合物及びアリールアセチレンアザ環式化合物、それらを含有する薬剤組成物、及び、ニコチンコリン作動性受容体の阻害薬としてのそれらの使用
US6624167B1 (en) * 2000-08-04 2003-09-23 Targacept, Inc. Pharmaceutical compositions and methods for use
US6881738B2 (en) 2001-07-19 2005-04-19 Medical College Of Georgia Research Institute Analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Also Published As

Publication number Publication date
TW200927745A (en) 2009-07-01
NO20091888L (no) 2005-10-03
UY28218A1 (es) 2005-06-30
AU2004217903A1 (en) 2004-09-16
EP2085395A1 (en) 2009-08-05
HK1130254A1 (en) 2009-12-24
NO332293B1 (no) 2012-08-20
JO2488B1 (en) 2009-10-05
ATE517893T1 (de) 2011-08-15
US20110152293A1 (en) 2011-06-23
AR070570A2 (es) 2010-04-21
CN101550132B (zh) 2012-03-28
EP1947100A1 (en) 2008-07-23
US20060094732A1 (en) 2006-05-04
AU2004217903B2 (en) 2010-03-04
EP2085395B1 (en) 2011-01-19
EA010870B1 (ru) 2008-12-30
GT200400033A (es) 2005-05-29
US20100010042A1 (en) 2010-01-14
SI2085395T1 (sl) 2011-05-31
PT2085395E (pt) 2011-04-20
CN101550132A (zh) 2009-10-07
DK2085395T3 (da) 2011-04-18
KR20120014236A (ko) 2012-02-16
US7714001B2 (en) 2010-05-11
PA8597201A1 (es) 2004-09-28
CN1756754A (zh) 2006-04-05
PL394604A1 (pl) 2011-07-18
PL2085395T3 (pl) 2011-05-31
JP4663627B2 (ja) 2011-04-06
US20140107164A1 (en) 2014-04-17
PE20040930A1 (es) 2005-02-18
TWI377204B (en) 2012-11-21
IL170155A (en) 2013-08-29
EA019240B1 (ru) 2014-02-28
EA200501425A1 (ru) 2006-02-24
PL378415A1 (pl) 2006-04-03
JP2006519868A (ja) 2006-08-31
CA2516514C (en) 2012-02-07
US20080293778A1 (en) 2008-11-27
ATE394394T1 (de) 2008-05-15
NO331920B1 (no) 2012-04-30
US20150164894A1 (en) 2015-06-18
NO20092231L (no) 2005-10-03
DE602004013553D1 (de) 2008-06-19
KR20090021227A (ko) 2009-02-27
US8633222B2 (en) 2014-01-21
JP5537085B2 (ja) 2014-07-02
JP5537084B2 (ja) 2014-07-02
DK1601670T3 (da) 2008-08-25
BRPI0409576A (pt) 2006-04-18
ZA200506790B (en) 2006-05-31
CN100526308C (zh) 2009-08-12
IL197890A (en) 2013-11-28
PL215059B1 (pl) 2013-10-31
HK1116800A1 (en) 2009-01-02
PL216979B1 (pl) 2014-06-30
AR070569A2 (es) 2010-04-21
CY1110391T1 (el) 2015-04-29
AU2008258188A1 (en) 2009-01-15
PT1601670E (pt) 2008-07-11
TWI339662B (en) 2011-04-01
SI1601670T1 (sl) 2008-10-31
EP1601670B1 (en) 2008-05-07
EA200900706A1 (ru) 2009-10-30
AR043469A1 (es) 2005-07-27
KR20090021228A (ko) 2009-02-27
PL1601670T3 (pl) 2008-10-31
ES2389106T3 (es) 2012-10-23
IL197889A (en) 2013-03-24
JP2010001296A (ja) 2010-01-07
NO20054120L (no) 2005-10-03
US20100267776A1 (en) 2010-10-21
CA2516514A1 (en) 2004-09-16
DE602004031165D1 (de) 2011-03-03
US20040176348A1 (en) 2004-09-09
KR100953150B1 (ko) 2010-04-19
EP1601670A1 (en) 2005-12-07
US8067443B2 (en) 2011-11-29
AU2008258187B2 (en) 2010-08-05
KR20060006006A (ko) 2006-01-18
TW200505909A (en) 2005-02-16
US8063068B2 (en) 2011-11-22
AU2008258188B2 (en) 2011-02-24
EP1947100B1 (en) 2011-07-27
JP2009292825A (ja) 2009-12-17
ES2385941T3 (es) 2012-08-03
CN101255155A (zh) 2008-09-03
CY1111615T1 (el) 2015-10-07
KR101185541B1 (ko) 2012-09-24
NZ541795A (en) 2008-03-28
CL2004000452A1 (es) 2005-05-20
MXPA05009386A (es) 2005-11-04
TW200927746A (en) 2009-07-01
HK1084949A1 (en) 2006-08-11
EA014714B1 (ru) 2011-02-28
KR101018083B1 (ko) 2011-03-02
US7098331B2 (en) 2006-08-29
PL394600A1 (pl) 2011-07-18
WO2004078752A1 (en) 2004-09-16
AU2008258187A1 (en) 2009-01-15
ES2309507T3 (es) 2008-12-16
EA200801764A1 (ru) 2008-12-30
ATE496046T1 (de) 2011-02-15

Similar Documents

Publication Publication Date Title
NO20054120D0 (no) Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav
NO20025488D0 (no) Stabiliserte tetrasoliumreagenssammensetninger og fremgangsmÕter for deres anvendelse
NO20025489L (no) Stabiliserte tetrasolium-fenasin-reagens-sammensetninger og fremgangsmåterfor deres anvendelse
NO20050830L (no) Acylerte heteroarylkondenserte sykloalkenylaminer og deres anvendelse som farmasoytiske midler
IS8320A (is) N-staðgengnir pýrasólýl-amidýl-bensimidasólýl
DK3266791T3 (da) Mærkede nukleotider
NO20050132D0 (no) Vaksinesammensetning
DE602004000470D1 (de) Fotomaske
NO20024742D0 (no) Heterocykliske forbindelser, deres fremstilling og anvendelse
DK1390066T3 (da) Vaccinesammensætning
DK1575618T3 (da) Dispergerbare farmaceutiske kombinationer
DE602004031845D1 (de) Ng
SE0302091L (sv) Genomföring
DK1587478T3 (da) Farmaceutisk sammensætning
IS8325A (is) Bóluefni
DE602004014804D1 (de) Haltenden tabletten
DE602004014239D1 (de) Betoniereinrichtung
DE602004018799D1 (de) Ng
ATE514681T1 (de) N-substituierte pyrazolylcarboxanilide
DK1667523T3 (da) DNA-vaccinesammensætninger og fremgangsmåder til deres anvendelse
DE112004000547D2 (de) Klappschalung
DE502004000456D1 (de) Ventilsteuerung
DE112004000405D2 (de) Federkonstruktion
DE602004028552D1 (de) Nockenwellenversteller
ATA19362002A (de) Verlorene schalung

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees